"Dr. Shmuel Cabilly holds a PhD in Immunology from the Hebrew University. In the Backman Research Institute of the City of Hope he initiated the development of a new breakthrough technology for recombinant antibody production, which was patented and known as the “Cabilly Patentâ€. Today, there are already more than 20 drugs in the market based on this technology, among which are Herceptin, Rituxan, Traceba, Raptiva, Xolair and others. Dr. Cabilly was also a co-founder and a Chief Scientist of Ethrog Biotechnology, where he invented dry buffer technologies enabling the production of a liquid free disposable apparatus for gel electrophoresis and a technology that enables the condensation of molecular separation zones to a small gel area. This technology was sold to Invitrogen in 2001. Dr. Cabilly is now an investor and serves as a board member of several companies."
Healthcare